Alterity Therapeutics Limited
ATHEHealthcare|Biotechnology|AU
$2.43
+0.21 (+9.46%)
DCF Value
$1.70
Tangible Book / Share
$117.86
Cash / Share
$102.94
About
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Stock Price
-30.6%(1Y)
1M
-20.8%
3M
-45.4%
6M
-47.9%
YTD
-21.1%
1Y
-35.2%
3Y
-8.3%
5Y
-79.8%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$41.2M
Employees11
CEODavid A. Stamler
IPO DateSep 29, 2003
Beta-0.03
52-Week Range$2.01 – $5.89
Avg Volume64,648
ExchangeNASDAQ
Websitealteritytx.com
Ownership
Float68.5%
Shares Outstanding16.9M
Recent Insider Trades
Marks Peter AshleyBUY
Aug 31, 202647,620 shares @ $0.50
Marks Peter AshleyBUY
Aug 31, 202647,620 shares @ $0.50
Stamler David AllenBUY
Aug 31, 202647,620 shares @ $0.50
Babarczy Julian MichaelAWARD
Jun 15, 20262,000,000 shares @ $1.00
Gozlan Lawrence BernardAWARD
Jun 15, 20261,000,000 shares @ $1.00
Peers
Recent News
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
Oct 30, 2026 · globenewswire.com
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Oct 9, 2026 · globenewswire.com
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
Oct 5, 2026 · globenewswire.com
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00
Sep 30, 2026 · defenseworld.net
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Sep 3, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:56 AM